Clinical trials
Malignancy clinical trials
Below are recruiting malignancy clinical trials, each written for real people, not researchers. We’re tracking 1,543 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06378437RecruitingPhase 1
GLB-001 for blood cancers that have returned or not responded
This trial is testing a new drug called GLB-001 for people with certain blood cancers or bone marrow disorders that have not gotten better with standard treatments. The goal is to see if the drug is safe and how well it works.
Hefei, AnhuiAges 18 years+ - NCT06650163RecruitingPhase 1
New imaging test for brain tumor surgery planning
This trial tests a new kind of PET scan that uses a special tracer (Zr-89 crefmirlimab berdoxam) to help doctors see brain tumors more clearly before surgery. If you are scheduled to have your brain tumor removed, this scan may give your surgeon extra information to guide the operation.
Los Angeles, CaliforniaAges 18 years+ - NCT06634589RecruitingPhase 1/Phase 2
Combination therapy for relapsed B-cell blood cancers
This study tests new drug combinations for people with B-cell blood cancers (like lymphoma or leukemia) that have come back or stopped responding to treatment. It aims to see if these combos are safe and can help fight the cancer.
Phoenix, ArizonaAges 18 years+ - NCT06630260RecruitingPhase 1/Phase 2
Avutometinib and Defactinib for brain tumors
This trial tests two oral drugs, avutometinib and defactinib, in people with aggressive brain tumors like glioblastoma. The goal is to see if this combination can shrink tumors or stop them from growing.
CambridgeAges 16 years+ - NCT06600789RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial is testing whether a new drug called CT7439 can help people with advanced solid tumors that have not responded to other treatments. It is a phase 1/2 study that also checks the drug's safety and how well it works.
Dallas, TexasAges 18 years+ - NCT06590961RecruitingPhase 1
A new drug (UBX-303061) for B-cell cancers that came back or didn't respond
A trial testing an experimental drug (UBX-303061) for people with certain B-cell blood cancers (like CLL, DLBCL, or MCL) that have returned or not responded to at least two other treatments. The goal is to see if the drug is safe and works when other options are no longer available.
Ann Arbor, MichiganAges 18 years+ - NCT06566079RecruitingPhase 1/Phase 2
Study of ISM6331 for advanced mesothelioma or other solid tumors
This trial tests a new drug called ISM6331 for people with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The drug targets a specific pathway that may help stop tumor growth.
Denver, ColoradoAges 18 years+ - NCT06552598RecruitingPhase 1
KD01 for advanced gynecologic cancers
This trial tests a new drug called KD01 for women with advanced gynecologic cancers (like cervical or endometrial cancer) that haven't responded to other treatments. It also has a separate part for younger women who want to preserve their fertility.
Wuhan, HubeiAges 18 years+ - NCT06542250RecruitingPhase 1/Phase 2
Study of a new immune therapy for relapsed B-cell cancers
This trial tests a new drug (AZD5492) that helps your immune system attack a protein (CD20) on cancer cells. It's for people with B-cell cancers that have come back after at least 2 prior treatments.
La Jolla, CaliforniaAges 18 years+ - NCT06515860Enrolling by invitation
NF1 Tumor Early Detection Study for Adults
This study is looking for adults with NF1 who have had a plexiform neurofibroma. It aims to find better ways to detect tumors early, which could help with treatment decisions.
Boston, MassachusettsAges 18 years+ - NCT05728658RecruitingPhase 1
Study of ICP-248 for relapsed or refractory B-cell cancers
This early-phase (Phase 1) study tests ICP-248 in people with certain B-cell cancers that have come back (relapsed) or did not respond to prior treatment (refractory). The goal is to learn the safest dose and whether it can help shrink or control the cancer.
Bengbu, AnhuiAges 18–80 - NCT06499350RecruitingPhase 1/Phase 2
New combo for advanced solid tumors after standard therapy
This trial tests a new combination of drugs (FC084CSA plus tislelizumab) for people with advanced solid tumors, especially lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It may be an option if you've tried standard treatments and they no longer work.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT06492070RecruitingPhase 2
Cooling therapy with or without cilostazol to prevent nerve damage from paclitaxel
This study tests whether cooling your hands and feet during chemotherapy, with or without the medicine cilostazol, can help prevent nerve damage (numbness, tingling, or pain) caused by the drug paclitaxel. It is for people with gynecologic cancers who are about to start or have just finished paclitaxel treatment.
Atlanta, GeorgiaAges 18 years+ - NCT06465433RecruitingPhase 2
Continued Tafasitamab Treatment for Blood Cancer
This trial allows people with blood cancers who are already benefiting from tafasitamab treatment in another study to keep receiving it. It helps ensure you can continue this therapy without interruption.
GyőrAges 18–99 - NCT06426992Recruiting
Microwave ablation for small liver tumors
This study tests a microwave ablation device to destroy small liver tumors (up to 4 cm) using heat, without major surgery. It is designed for patients with limited disease (1 or 2 tumors) and good liver function.
SeoulAges 20–85 - NCT06401356RecruitingPhase 3
Long-term study for people already taking pelabresib
This is a follow-up study for people who are already taking the drug pelabresib in another trial and are doing well on it. It allows you to continue receiving pelabresib and monitors your health over a longer period.
Los Angeles, CaliforniaAges 18 years+ - NCT06387082RecruitingPhase 1
Study of an investigational pill for certain leukemias
This study tests an experimental pill (HMPL-506) for people with certain types of leukemia (AML or ALL) that have not responded to standard treatments. The pill targets specific gene changes (MLL rearrangement or NPM1 mutation) to try to kill the cancer cells.
ChangshaAges 18 years+ - NCT06383871RecruitingPhase 1
A study of the new drug HRS-7058 for advanced solid tumors
This is a phase 1 study testing a new oral drug called HRS-7058 for people with advanced solid tumors that have not responded to other treatments. The main goal is to find a safe dose and see how well the drug works.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06383572RecruitingPhase 1/Phase 2
Modified immune cells for blood cancers after chemo
This trial tests a new type of immune cell (NK cell) that has been engineered to target a protein called PRAME found on some cancer cells. It is for people with certain types of blood cancer (AML, MDS, or CMML) that have come back or not responded to treatment.
Houston, TexasAges 18–80 - NCT06397560Recruiting
Proton radiation for returning brain tumors
This trial tests a new type of proton radiation therapy given at a lower dose rate to treat brain tumors that have come back after previous radiation. The goal is to see if it's safe and effective.
Boca Raton, FloridaAges 18 years+ - NCT06355895Recruiting
Liver size and radiation therapy for abdominal cancers
This study looks at how changes in liver size affect the planning and delivery of radiation therapy for cancers in the upper abdomen, such as pancreatic, bile duct, or liver cancer. It aims to improve treatment accuracy.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06328686RecruitingEarly Phase 1
Arginine and whole brain radiation for brain metastases
This trial tests whether taking arginine (an amino acid) during whole brain radiation therapy can help people with brain metastases from any type of cancer. It looks at how the treatment affects the body and may improve outcomes.
Atlanta, GeorgiaAges 18 years+ - NCT06326463RecruitingPhase 1
CAR T-cell therapy for CD70-positive blood cancers in children
This trial tests a special immune cell therapy (CAR T-cells) that targets a protein called CD70 on blood cancer cells. It is for children and young adults up to age 21 whose cancer has come back or hasn't gotten better with other treatments.
Memphis, TennesseeAges Up to 21 years
Hear when a new Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for malignancy?
- Yes. Clin2 currently lists 1,543 recruiting malignancy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a malignancy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a malignancy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.